Rivaroxaban attenuates the cardiovascular PAR1-related inflammation, fibrosis and atherogenicity in experimental hypertensive/ hypercholesterolemia rat model
Shamardl, H., Hussien, E., Sofi, M., Sadik, S. (2024). Rivaroxaban attenuates the cardiovascular PAR1-related inflammation, fibrosis and atherogenicity in experimental hypertensive/ hypercholesterolemia rat model. EKB Journal Management System, (), -. doi: 10.21608/ejh.2024.301628.2101
Hanan A Shamardl; Eman A Hussien; Marwa A Sofi; Sawsan A Sadik. "Rivaroxaban attenuates the cardiovascular PAR1-related inflammation, fibrosis and atherogenicity in experimental hypertensive/ hypercholesterolemia rat model". EKB Journal Management System, , , 2024, -. doi: 10.21608/ejh.2024.301628.2101
Shamardl, H., Hussien, E., Sofi, M., Sadik, S. (2024). 'Rivaroxaban attenuates the cardiovascular PAR1-related inflammation, fibrosis and atherogenicity in experimental hypertensive/ hypercholesterolemia rat model', EKB Journal Management System, (), pp. -. doi: 10.21608/ejh.2024.301628.2101
Shamardl, H., Hussien, E., Sofi, M., Sadik, S. Rivaroxaban attenuates the cardiovascular PAR1-related inflammation, fibrosis and atherogenicity in experimental hypertensive/ hypercholesterolemia rat model. EKB Journal Management System, 2024; (): -. doi: 10.21608/ejh.2024.301628.2101